In adults, muscle diseases are usually chronic long-term conditions that do not have a definitive cure. Supportive care has been shown to reduce complications from muscle disease and improved survival in some cases. However, there has been limited research to evaluate interventions that may improve quality of life (QoL) with this patient group. The QoL of those with MD is not just affected by the severity of their MD but also a variety of psychological variables. Based upon the knowledge of these psychological variables the investigators feel that a particular type of psychological intervention known as "acceptance and commitment therapy" (ACT) could potentially improve QoL in those with MD. The investigators therefore propose to test whether ACT does in fact improve QoL in those with MD by randomising 154 patients to receive either standard medical care plus a guided self-help ACT programme, or standard medical care only.
Previous research has shown that while QoL is determined by the severity of the MD, this does not explain all aspects of the reduced QoL of those with MD. Previous research suggested that a cognitive behavioural approach using Acceptance and Commitment Therapy (ACT) would best suit those with MD. A pilot study of this approach in seven participants with MD was promising, and has led to this definitive trial of ACT. The aim of this study is to determine the efficacy of an ACT intervention to improve the QoL of individuals with MD. Patients with one of the following muscle diseases will be recruited: limb girdle muscular dystrophy, dystrophinopathies resulting in a Becker' muscular dystrophy phenotype, facioscapulohumeral muscular dystrophy and inclusion body myositis. Patients will be recruited primarily through muscle clinics at King's College Hospital (KCH) and The Royal London Hospital (RLH) but also via Muscular Dystrophy UK (MDUK) and UK registries of patients with these muscle diseases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
155
Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
King's College Hospital; The Royal London Hospital; University Hospital Southampton; King's College London
London, United Kingdom
Individualised Neuromuscular Quality of Life Questionnaire (INQoL) - Life areas
Measures impact of MD on life areas: activities, independence, social functioning, emotional functioning and body image.
Time frame: 9 weeks post randomisation
Individualised Neuromuscular Quality of Life Questionnaire (INQoL) - Symptom impact domains
Measures the impact of key muscle disease symptoms: weakness, fatigue and pain.
Time frame: 9 weeks post randomisation
Work and Social Adjustment Scale (WSAS)
Assesses how much symptoms interfere with participation in life i.e. work, home management, social, private and relationships.
Time frame: 9 weeks post randomisation
Hospital Anxiety and Depression Scale (HADS)
Measures mood.
Time frame: 9 weeks post randomisation
Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)
Measures functional impairment.
Time frame: 9 weeks post randomisation
Acceptance and Action Questionnaire (AAQ-II)
Measures psychological flexibility.
Time frame: 9 weeks post randomisation
Mindfulness Attention Awareness Scale (MAAS)
Measures dispositional open awareness of and attention to the present moment.
Time frame: 9 weeks post randomisation
Committed Action Scale (CAS)
Measures commitment towards goals.
Time frame: 9 weeks post randomisation
IBM Functional Rating Scale
Assesses function in people with Inclusion Body Myositis.
Time frame: 9 weeks post randomisation
Patient Global Impression of Change scale (PGIC)
Assesses patient's own impression of change during the course of the study.
Time frame: 9 weeks post randomisation
Patient rating of treatment satisfaction
Measures patient's satisfaction with the treatment they have received.
Time frame: 9 weeks post randomisation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.